▾ G11 Media Network: | ChannelCity | ImpresaCity | SecurityOpenLab | GreenCity | Italian Channel Awards | Italian Project Awards | ...
InnovationOpenLab

IQVIA Reports First-Quarter 2024 Results

IQVIA Holdings Inc. (“IQVIA”) (NYSE:IQV), a leading global provider of advanced analytics, technology solutions, and clinical research services to the life sciences industry, today reported financ...

Business Wire
  • Revenue of $3,737 million
  • GAAP Net Income of $288 million, Adjusted EBITDA of $862 million
  • GAAP Diluted Earnings per Share of $1.56, Adjusted Diluted Earnings per Share of $2.54
  • R&D Solutions quarterly bookings of $2.6 billion, representing a book-to-bill ratio of 1.23x
  • R&D Solutions contracted backlog of $30.1 billion, up 7.9 percent year-over-year

RESEARCH TRIANGLE PARK, N.C.: IQVIA Holdings Inc. (“IQVIA”) (NYSE:IQV), a leading global provider of advanced analytics, technology solutions, and clinical research services to the life sciences industry, today reported financial results for the quarter ended March 31, 2024.

First-Quarter 2024 Operating Results
Revenue for the first quarter of $3,737 million increased 2.3 percent on a reported basis and 2.9 percent at constant currency, compared to the first quarter of 2023. Technology & Analytics Solutions (TAS) revenue of $1,453 million increased 0.6 percent on a reported basis and 1.0 percent at constant currency. Research & Development Solutions (R&DS) revenue of $2,095 million increased 3.4 percent on a reported basis and 3.8 percent at constant currency. Excluding the impact of pass throughs, R&DS revenue grew 6.9 percent on a reported basis. Contract Sales & Medical Solutions (CSMS) revenue of $189 million increased 3.8 percent on a reported basis and 7.1 percent at constant currency.

As of March 31, 2024, R&DS contracted backlog, including reimbursed expenses, was $30.1 billion, growing 7.9 percent year-over-year and 8.3 percent at constant currency. The company expects approximately $7.7 billion of this backlog to convert to revenue in the next twelve months. The first-quarter book-to-bill ratio was 1.23x, including cancellation of a large central nervous system program (over 1.3x excluding this cancellation). For the twelve months ended March 31, 2024, the book-to-bill ratio was 1.26x.

“The IQVIA team executed well in the first quarter, including strong bookings and robust free cash flow generation,” stated Ari Bousbib, chairman and CEO of IQVIA. "The TAS segment revenue grew as expected in the quarter, and we continue to anticipate gradual improvement later in the year. The R&DS segment continued to see strong demand in the quarter, with healthy RFP growth. We anticipate R&DS will grow consistent with our prior expectations, bolstered by strong bookings and our industry leading backlog of over $30 billion."

First-quarter GAAP Net Income was $288 million and GAAP Diluted Earnings per Share was $1.56. Adjusted Net Income was $468 million and Adjusted Diluted Earnings per Share was $2.54. Adjusted EBITDA was $862 million, up 1.3 percent year-over-year.

Financial Position
As of March 31, 2024, cash and cash equivalents were $1,444 million and debt was $13,536 million, resulting in net debt of $12,092 million. IQVIA’s Net Leverage Ratio was 3.38x trailing twelve-month Adjusted EBITDA. For the first quarter, Operating Cash Flow was $522 million and Free Cash Flow was $377 million.

Full-Year 2024 Guidance
The company reaffirms its full-year revenue guidance on a constant currency basis. After adjusting for the $75 million impact of the strengthening US dollar since February 12, 2024, the revenue guidance is now $15,325 million to $15,575 million on a reported basis, resulting in growth of 2.3 to 3.9 percent. This guidance represents a year-over-year foreign exchange headwind of ~100 basis points, versus the ~50 basis points headwind included in the previous guidance. This guidance continues to assume approximately $300 million of COVID-related revenue step down as well as ~100 basis points of contribution from acquisitions.

The company reaffirms its full-year Adjusted EBITDA guidance of $3,700 million to $3,800 million, representing growth of 3.7 to 6.5 percent.

The company reaffirms its full-year Adjusted Diluted EPS guidance of $10.95 to $11.25, up 7.4 to 10.3 percent year-over-year.

All financial guidance assumes foreign currency exchange rates as of April 30, 2024 remain in effect for the forecast period.

Webcast & Conference Call Details
IQVIA will host a conference call at 9:00 a.m. Eastern Time today to discuss its first-quarter 2024 results and its second-quarter and full-year 2024 guidance. To listen to the event and view the presentation slides via webcast, join from the IQVIA Investor Relations website at http://ir.iqvia.com. To participate in the conference call, interested parties must register in advance by clicking on this link. Following registration, participants will receive a confirmation email containing details on how to join the conference call, including the dial-in and a unique passcode and registrant ID. At the time of the live event, registered participants connect to the call using the information provided in the confirmation email and will be placed directly into the call.

About IQVIA
IQVIA (NYSE:IQV) is a leading global provider of advanced analytics, technology solutions, and clinical research services to the life sciences industry. IQVIA creates intelligent connections across all aspects of healthcare through its analytics, transformative technology, big data resources, extensive domain expertise and network of partners. IQVIA Connected Intelligence™ delivers actionable insights and powerful solutions with speed and agility — enabling customers to accelerate the clinical development and commercialization of innovative medical treatments that improve healthcare outcomes for patients. With approximately 87,000 employees, IQVIA conducts operations in more than 100 countries.

IQVIA is a global leader in protecting individual patient privacy. The company uses a wide variety of privacy-enhancing technologies and safeguards to protect individual privacy while generating and analyzing information on a scale that helps healthcare stakeholders identify disease patterns and correlate with the precise treatment path and therapy needed for better outcomes. IQVIA’s insights and execution capabilities help biotech, medical device and pharmaceutical companies, medical researchers, government agencies, payers and other healthcare stakeholders tap into a deeper understanding of diseases, human behaviors and scientific advances, in an effort to advance their path toward cures. To learn more, visit www.iqvia.com.

Cautionary Statements Regarding Forward-Looking Statements
This press release contains “forward-looking statements” within the meaning of the federal securities laws, including Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including, without limitation, our full-year 2024 guidance. In this context, forward-looking statements often address expected future business and financial performance and financial condition, and often contain words such as “expect,” “assume,” “anticipate,” “intend,” “plan,” “forecast,” “believe,” “seek,” “see,” “will,” “would,” “target,” similar expressions, and variations or negatives of these words that are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Actual results may differ materially from our expectations due to a number of factors, including, but not limited to, the following: business disruptions caused by natural disasters, pandemics such as the COVID-19 (coronavirus) outbreak, including any variants, and the public health policy responses to the outbreak, and international conflicts or other disruptions outside of our control such as the current situation in Ukraine and Russia; most of our contracts may be terminated on short notice, and we may lose or experience delays with large client contracts or be unable to enter into new contracts; the market for our services may not grow as we expect; we may be unable to successfully develop and market new services or enter new markets; imposition of restrictions on our use of data by data suppliers or their refusal to license data to us; any failure by us to comply with contractual, regulatory or ethical requirements under our contracts, including current or future changes to data protection and privacy laws; breaches or misuse of our or our outsourcing partners’ security or communications systems; failure to meet our productivity or business transformation objectives; failure to successfully invest in growth opportunities; our ability to protect our intellectual property rights and our susceptibility to claims by others that we are infringing on their intellectual property rights; the expiration or inability to acquire third party licenses for technology or intellectual property; any failure by us to accurately and timely price and formulate cost estimates for contracts, or to document change orders; hardware and software failures, delays in the operation of our computer and communications systems or the failure to implement system enhancements; the rate at which our backlog converts to revenue; our ability to acquire, develop and implement technology necessary for our business; consolidation in the industries in which our clients operate; risks related to client or therapeutic concentration; government regulators or our customers may limit the number or scope of indications for medicines and treatments or withdraw products from the market, and government regulators may impose new regulatory requirements or may adopt new regulations affecting the biopharmaceutical industry; the risks associated with operating on a global basis, including currency or exchange rate fluctuations and legal compliance, including anti-corruption laws; risks related to changes in accounting standards; general economic conditions in the markets in which we operate, including financial market conditions, inflation, and risks related to sales to government entities; the impact of changes in tax laws and regulations; and our ability to successfully integrate, and achieve expected benefits from, our acquired businesses. For a further discussion of the risks relating to our business, see the “Risk Factors” in our annual report on Form 10-K for the fiscal year ended December 31, 2023, filed with the Securities and Exchange Commission (the "SEC"), as such factors may be amended or updated from time to time in our subsequent periodic and other filings with the SEC, which are accessible on the SEC’s website at www.sec.gov. These factors should not be construed as exhaustive and should be read in conjunction with the other cautionary statements that are included in this release and in our filings with the SEC. We assume no obligation to update any such forward-looking statement after the date of this release, whether as a result of new information, future developments or otherwise.

Note on Non-GAAP Financial Measures
This release includes information based on financial measures that are not recognized under generally accepted accounting principles in the United States ("GAAP"), such as Adjusted EBITDA, Adjusted Net Income, Adjusted Diluted Earnings per Share, Gross Leverage Ratio, Net Leverage Ratio and Free Cash Flow. Non-GAAP financial measures are presented only as a supplement to the company’s financial statements based on GAAP. Non-GAAP financial information is provided to enhance understanding of the company’s financial performance, but none of these non-GAAP financial measures are recognized terms under GAAP, and non-GAAP measures should not be considered in isolation from, or as a substitute analysis for, the company’s results of operations as determined in accordance with GAAP. The company uses non-GAAP measures in its operational and financial decision making, and believes that it is useful to exclude certain items in order to focus on what it regards to be a more meaningful indicator of the underlying operating performance of the business. For example, the company excludes all the amortization of intangible assets associated with acquired customer relationships and backlog, databases, non-compete agreements, trademarks and trade names from non-GAAP expense and income measures as such amounts can be significantly impacted by the timing and size of acquisitions. Although we exclude amortization of acquired intangible assets from our non-GAAP expenses, we believe that it is important for investors to understand that revenue generated from such intangibles is included within revenue in determining net income. As a result, internal management reports feature non-GAAP measures which are also used to prepare strategic plans and annual budgets and review management compensation. The company also believes that investors may find non-GAAP financial measures useful for the same reasons, although investors are cautioned that non-GAAP financial measures are not a substitute for GAAP disclosures.

The non-GAAP financial measures are not presented in accordance with GAAP. Please refer to the schedules attached to this release for reconciliations of non-GAAP financial measures contained herein to the most directly comparable GAAP measures. Our full-year 2024 guidance measures (other than revenue) are provided on a non-GAAP basis without a reconciliation to the most directly comparable GAAP measure because the company is unable to predict with a reasonable degree of certainty certain items contained in the GAAP measures without unreasonable efforts. For the same reasons, the company is unable to address the probable significance of the unavailable information. Such items include, but are not limited to, acquisition related expenses, restructuring and related expenses, stock-based compensation and other items not reflective of the company's ongoing operations.

Non-GAAP measures are frequently used by securities analysts, investors and other interested parties in their evaluation of companies comparable to the company, many of which present non-GAAP measures when reporting their results. Non-GAAP measures have limitations as an analytical tool. They are not presentations made in accordance with GAAP, are not measures of financial condition or liquidity and should not be considered as an alternative to profit or loss for the period determined in accordance with GAAP or operating cash flows determined in accordance with GAAP. Non-GAAP measures are not necessarily comparable to similarly titled measures used by other companies. As a result, you should not consider such performance measures in isolation from, or as a substitute analysis for, the company’s results of operations as determined in accordance with GAAP.

IQVIAFIN

 
 
 

Table 1
IQVIA HOLDINGS INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF INCOME
(preliminary and unaudited) 

 

 

 

Three Months Ended March 31,

(in millions, except per share data)

 

 

2024

 

 

 

2023

 

Revenues

 

$

3,737

 

 

$

3,652

 

Cost of revenues, exclusive of depreciation and amortization

 

 

2,444

 

 

 

2,398

 

Selling, general and administrative expenses

 

 

508

 

 

 

513

 

Depreciation and amortization

 

 

264

 

 

 

253

 

Restructuring costs

 

 

15

 

 

 

17

 

Income from operations

 

 

506

 

 

 

471

 

Interest income

 

 

(11

)

 

 

(6

)

Interest expense

 

 

166

 

 

 

141

 

Other expense (income), net

 

 

11

 

 

 

(26

)

Income before income taxes and equity in losses of unconsolidated affiliates

 

 

340

 

 

 

362

 

Income tax expense

 

 

49

 

 

 

71

 

Income before equity in losses of unconsolidated affiliates

 

 

291

 

 

 

291

 

Equity in losses of unconsolidated affiliates

 

 

(3

)

 

 

(2

)

Net income

 

$

288

 

 

$

289

 

Earnings per share attributable to common stockholders:

 

 

 

 

Basic

 

$

1.58

 

 

$

1.56

 

Diluted

 

$

1.56

 

 

$

1.53

 

Weighted average common shares outstanding:

 

 

 

 

Basic

 

 

181.9

 

 

 

185.8

 

Diluted

 

 

184.3

 

 

 

188.6

 

 
 
 
 

Table 2
IQVIA HOLDINGS INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED BALANCE SHEETS
(preliminary and unaudited) 

 

(in millions, except per share data)

 

March 31, 2024

 

December 31, 2023

ASSETS

 

 

 

 

Current assets:

 

 

 

 

Cash and cash equivalents

 

$

1,444

 

 

$

1,376

 

Trade accounts receivable and unbilled services, net

 

 

3,426

 

 

 

3,381

 

Prepaid expenses

 

 

173

 

 

 

141

 

Income taxes receivable

 

 

35

 

 

 

32

 

Investments in debt, equity and other securities

 

 

131

 

 

 

120

 

Other current assets and receivables

 

 

442

 

 

 

546

 

Total current assets

 

 

5,651

 

 

 

5,596

 

Property and equipment, net

 

 

513

 

 

 

523

 

Operating lease right-of-use assets

 

 

278

 

 

 

296

 

Investments in debt, equity and other securities

 

 

109

 

 

 

105

 

Investments in unconsolidated affiliates

 

 

154

 

 

 

134

 

Goodwill

 

 

14,516

 

 

 

14,567

 

Other identifiable intangibles, net

 

 

4,725

 

 

 

4,839

 

Deferred income taxes

 

 

152

 

 

 

166

 

Deposits and other assets, net

 

 

476

 

 

 

455

 

Total assets

 

$

26,574

 

 

$

26,681

 

LIABILITIES AND STOCKHOLDERS’ EQUITY

 

 

 

 

Current liabilities:

 

 

 

 

Accounts payable and accrued expenses

 

$

3,455

 

 

$

3,564

 

Unearned income

 

 

1,914

 

 

 

1,799

 

Income taxes payable

 

 

155

 

 

If you liked this article and want to stay up to date with news from InnovationOpenLab.com subscribe to ours Free newsletter.

Related news

Last News

Gyala: a new "Made in Italy" cybersecurity

With a proven track record in the defence field, Gyala now also brings its cybersecurity technologies to the wider enterprise audience

ITALIAN PROJECT AWARDS 2023: the best IT projects of the year, awarded

Now in its third edition, the initiative is targeted at the ICT professional world and honours projects based on innovative ideas and technologies, realised…

I3P launches the Cybersecurity Incubation Program

The I3P's initiative is promoted together with the National Cybersecurity Agency in collaboration with Leonardo and C*Sparks.

iVis Technologies enables remotely-controlled corneal telesurgery

It's based on Italian technologies the first successful intercontinental telesurgery intervention for keratoconus carried out remotely, connecting Bari…

Most read

Genesys Recognizes Modivcare as Winner of EX Mobilizer Award

Genesys®, a global cloud leader in AI-powered experience orchestration, announced Modivcare as the winner of the Employee Experience (EX) Mobilizer category…

Gyala: a new "Made in Italy" cybersecurity

With a proven track record in the defence field, Gyala now also brings its cybersecurity technologies to the wider enterprise audience

MDS Property Management Software Achieves SOC 2 Compliance

#newyorkcity--MDS Property Management Software is pleased to announce the successful completion of its System and Organization Controls (SOC) 2 audit,…

IP Infusion Hosts the First Telecom Infra Project MANTRA Proof of Concept…

#TIPMANTRA--IP Infusion, a global leader in open networking solutions, has completed the Phase 1 Proof of Concept (PoC) in its lab for the Telecom Infra…